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Abstract
Background: The aromatic amine 4-aminobiphenyl (4-ABP) is an environmental and occupational
contaminant known to be a major etiological agent of human bladder cancer. 4-ABP metabolites
are able to form DNA adducts that may induce mutations and initiate bladder carcinogenesis. Cells
exposed to 4-ABP may develop resistance to the carcinogen. The aim of the present study was to
detect and identify proteins whose expression is altered in the bladder carcinoma RT112 sub-lines
selected for acquired resistance to 4-ABP, in order to disentangle the mechanisms.
Results: Differential proteome analysis of cell lysates showed an overall perturbation in cell
metabolism and energy pathways in the 4-ABP-resistant human urothelial clones, with over-
expression of membrane trafficking proteins such as annexin 2. The resistant clones had altered
expression of many proteins linked directly (i.e. lamin A/C, programmed cell death 6 interacting
protein) or indirectly (i.e. 94 kDa glucose-regulated protein, fatty acid-binding protein) to
decreased apoptosis, suggesting that resistance to 4-ABP might be associated with low apoptotic
activity.
Conclusion: Our data provide evidence that deregulation of apoptosis and membrane trafficking
proteins might be strongly implicated in the selection of carcinogen resistant cells. Some of these
proteins might have potential as biomarkers of resistance and cancer risk.
Background
Resistance is a complex process, very likely the result of
multiple and often overlapping routes that can be affected
by a variety of host and acquired factors often not clearly
defined. Proteomic techniques, that allow observation of
changes in multiple proteins at once, might play a key role
in understanding the development of cell resistance to
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drugs, helping clarify the mechanisms through which cells
escape their effects [1-3].
Although the multifactorial aspect of resistance still needs
to be disentangled, it is generally accepted that the selec-
tive pressure exerted by drugs, combined with cell hetero-
geneity, is the driving force for drug resistance. Specific
carcinogens, that can form adducts to DNA, can even
select carcinogen-resistant tumour cells [4] that may have
sustained extensive DNA damage yet somehow escape
death. The phenotypic and potential genotypic differences
in the surviving cells may convey a selective survival
advantage, which may disrupt cell death/growth homeos-
tasis and predispose these cells to progression. Thus, as
anticancer agents drive carcinogenesis by means of natural
selection, environmental agents might act in the same
manner. As an example, carcinogens from inhaled
tobacco smoke not only induce mutations, but also set up
a selection pressure that favours mutants resistant to the
cytotoxic effects of smoking [5].
We have already observed that in bladder cells the DNA
bulky adducts formed by the carcinogen 4-aminobiphe-
nyl (4-ABP) were proportionate to the tumour grades [6],
suggesting again that cancer development can lead to "tol-
erance" to DNA damage, through clonal cell selection. To
date, there is no clear characterisation of this phenotype
and the mechanisms by which cells develop resistance
toward an environmental carcinogen are poorly under-
stood. It is likely that a combination of several factors is
involved, as in drug resistance. Thus a proteomic
approach is of interest to compare protein profiles
between carcinogen-resistant cells and their non-resistant
counterparts.
In the present study we treated the human transitional
bladder cell carcinoma line RT112 with 4-ABP to select for
cells developing resistance to this compound. 4-ABP is an
environmental and occupational contaminant that can
interact with DNA to form bulky adducts through its met-
abolically activated electrophilic derivatives, and induces
bladder carcinogenesis in humans [6].
We used a proteomic approach to examine the overall
protein expression profile and characterize its alteration
in sub-lines selected for resistance to 4-ABP, in order to
gain insight into (i) the mechanisms involved in the cells'
response to 4-ABP exposure, and (ii) the potential mech-
anisms by which resistance can arise.
Results
Resistant clones
The first step was to establish derivatives of the RT112 cell
line resistance to the carcinogen 4-ABP. We treated cells
with a panel of carcinogen concentrations in order to
obtain cytotoxicity curves. Details of selected 4-ABP resist-
ant clones will be reported in a forthcoming publication
(F. Saletta et al., submitted). Briefly, 4-ABP resistant cells
were established by treatment with a carcinogen concen-
tration that normally kills > 99% of RT112 cells (125 ng/
mL). After treatment, viable single-cell clones were
obtained by limiting dilution. The relative resistance of
isolated clones was evaluated by treating cells with 4-ABP
(75–175 ng/mL) and viability was measured by Trypan
Blue. Thus, we developed two cell sublines, RT5 and
RT11, showing a high degree of resistance (respectively
90% and 88% after first treatment of 125 ng/mL 4-ABP;
30% and 31% after second treatment of 125 ng/mL 4-ABP
as shown in figure 1).
Proteomic analysis
The expression patterns of proteins of the 4-ABP-resistant
RT5 and RT11 clones were compared with the parental
RT112 cells using 2-DE image analysis software.
Figure 2 shows the 2-DE average gel representative of the
RT112 parental cell line. The inserts provide a view of the
expression pattern and the relative abundance of the pro-
teins whose expression was significantly different in the
parental cells and both 4-ABP-resistant clones.
Image analysis detected a comparable number of spots in
the three average gels from the three cell lines (spot
number 1015 ± 40, mean ± SD). The number of spots
detected in each set of three replicates was reproducible
(coefficient of variation, CV 6–17%), as was their spot
intensity (CV 15–29%). Spots showing the highest varia-
tion were generally those not completely resolved from
surrounding proteins, or localized at the extreme pI val-
ues.
Overall, fourteen protein species showed a statistically sig-
nificant change in abundance of 1.5 times or more, as a
result of the cell line phenotype. Results of identifications
are summarized in Table 1.
The difference on 2-DE gel between expected and
observed MW of calreticulin (CALR, spot 146) (Table 1)
comes as no surprise, since the electrophoretic mobility of
CALR is known to be anomalous, with the 46-kD protein
showing 2-DE migration compatible with a molecular
size of 60-kD [7].
Some of the proteins such as annexin 2 (ANXA2, spot
479), transgelin 2 (TANGL2, spot 680) and NADH-ubiq-
uinone oxidoreductase 30 kDa subunit (NDUFS3, spot
906) showed a difference between the predicted and
observed pI value (Table 1). The most straightforward
interpretation of these shifts is the presence of protein var-
iants differing in charge through aminoacid differences orProteome Science 2007, 5:6 http://www.proteomesci.com/content/5/1/6
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post-translational modifications (PTM). As regards
ANXA2, a slightly longer isoform of ANXA2 with a more
basic pI (8.7) but no real change in the MW has been iden-
tified in our MS/MS search using another database, the
NCBInr (v.20060828) (ANXA2, isoform 1,
NP_001002858, # valid peptide match 11, coverage
31%). This might therefore be the variant we found in our
2-DE gel. Unfortunately, no information was found avail-
able about its biological relevance.
A multiple database (UniProt_Swiss Prot and NCBInr)
search strategy did not help find any further variant of
TANGL2 and NDUFS3 that might explain the pI variation
observed. However, both TANGL2 and NDUFS3 pre-
sented a pI shifted toward the acidic region of the 2-DE
gel, suggesting that some post-translational modifications
(PTM) such as phosphorylation had occurred. These pro-
teins have multiple phosphorylation sites, as predicted by
bioinformatics tools such as NetPhos [8]. The presence of
such PTM can shift the pI toward an acidic value; conse-
quently the modified proteins might migrate differently
on the 2-DE gels, as predicted by ProMoST [9], a web-tool
that calculates the effect of single/multiple modifications
of a protein and provides the graphic representation of the
gel shifts due to PTM.
Protein expression profile in 4-ABP-resistant clones and 
the RT112 parental urothelial cell line
As shown in Figure 2, histogram inserts, in the resistant
cells the expression levels of ANXA2, 94 kDa glucose-reg-
ulated protein (GRP94) and lamin A/C (LMNA) were
twice or more of the parental line. Five proteins were
down regulated in both resistant clones. The abundance
of the mitochondrial elongation factor Tu (TUFM) was
more than halved compared to the parental line. Simi-
larly, the expression level of 3-hydroxyisobutyryl-CoA
hydrolase, isoform 1 (HIBCH), triosephosphate isomer-
ase (TPI) and adipocyte fatty acid-binding protein
(FABP4) was more than two times lower in the RT5 clone
than in the RT112 cells. In the RT11 clone, the abundance
of these proteins did not decrease two fold. Significant
down regulation of NDUFS3 was also observed in the
resistant cells, where decreases were 1.7 and 1.3-fold.
Protein expression differences between the 4-ABP-
resistant clones
A number of proteins were differently expressed only in
the clone RT5 (Figure 2, histogram inserts). The most
striking aspect was the marked decrease in the expression
of TAGNL2, whose abundance in the RT5 cells was 5 times
lower than in the RT11 and 6.7 times lower than the
parental line. The pattern of expression was similar for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
whose level was significantly lower in the RT5 clone. This
clone showed a decrease in the expression of CALR, but
the difference was significant only compared to the paren-
tal cells.
Three protein species were significantly down regulated
only in clone RT11 compared to clone RT5 and the paren-
tal line. The abundances of the PDCD6IP and two puta-
tive isoforms of aldehyde dehydrogenase 1 family,
member A3 (ALDH1A3) were about half that of the RT5
clone and the parent cell population.
Western blot
Western blotting of lysates prepared from the parental
RT112 and the 4-ABP-resistant clones RT5 and RT11 was
used to investigate some of the most important factors
regulating apoptosis. Among the Bcl-2 family, the balance
between the Bcl-2 and the Bax members is essential to the
apoptotic potential of the cells, low apoptotic activity
often being associated with a low Bax/Bcl-2 ratio.
Cytotoxicity curves for human bladder cancer cell line  RT112 and 4-ABP resistant clones RT5 and RT11 after the  first 4-ABP treatment panel (A); after the second 4-ABP  treatment, panel (B) Figure 1
Cytotoxicity curves for human bladder cancer cell line 
RT112 and 4-ABP resistant clones RT5 and RT11 after the 
first 4-ABP treatment panel (A); after the second 4-ABP 
treatment, panel (B).Proteome Science 2007, 5:6 http://www.proteomesci.com/content/5/1/6
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As reported in figure 3, both resistant clones showed
markedly higher expression of the anti-apoptotic Bcl-2
protein than the parent line. The effect on the Bax level
was less evident, though the Bax/Bcl-2 expression ratio
was lower in the 4-ABP resistant clone (data not shown).
Consistent with the lower apoptotic ability in the resistant
clones is the increased presence of inactive caspase-3 pre-
cursor (Cpp32 precursor) and the lower levels of the
cleaved caspase-3 form (Cpp32), which is proteolytically
generated during apoptosis (figure 3). The level of the
MAD2 protein, required for mitotic checkpoint control,
was also lower in the resistant clones than in the parent
cells (figure 3).
Discussion
We have successfully developed two cell lines (RT5 and
RT11), from the parental human bladder cancer RT112
cell line that show resistance to the environmental carcin-
ogen 4-ABP. Here we report the comparative proteomic
study to identify the differences in abundance of proteins
in the sensitive and 4-ABP-resistant RT112 urothelial cells.
The aim was to gain insight into how changes in protein
profiles contribute to the development of resistance to the
environmental carcinogen 4-ABP. Our data as a whole
provide evidence that deregulation of apoptosis might be
strongly implicated in the selection of such carcinogen-
resistant cells.
Colloidal CBB-stained 2-DE gel (Progenesis average gel image) of cell protein extract (300 μg) from human bladder cancer cell  line RT112 Figure 2
Colloidal CBB-stained 2-DE gel (Progenesis average gel image) of cell protein extract (300 μg) from human bladder cancer cell 
line RT112. The inserts show the expression patterns for the selected protein species whose abundance changed significantly 
(one-way ANOVA, Tukey Kramer HSD p < 0.05) in the human bladder cancer cell line RT112 and the 4-ABP resistant clones 
RT5 and RT11. Each bar represents the average spot abundance expressed as normalised volume ± SD. The vertical axis shows 
the spot normalised volume. Numbers in parentheses indicate protein expression difference (-fold). Spot numbers are from 
the Progenesis image analysis results.Proteome Science 2007, 5:6 http://www.proteomesci.com/content/5/1/6
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Although the parental RT112 cell line has been reported
to have relatively low susceptibility to apoptosis [10,11],
interestingly both resistant clones showed over-expres-
sion of two proteins, GRP94 and LMNA, linked to a
decrease in apoptosis [12,13], suggesting that resistance to
4-ABP might be associated with a further loss of apoptotic
capacity. Moreover, the apoptotic resistant phenotype of
the clones might be reinforced by the down-regulation of
FABP4, a fatty acid-binding protein, whose expression is
linked to the apoptotic process [14,15]. In Additional file
1 we expanded upon the probable role of these proteins
in conferring resistance to apoptosis.
To confirm that the observed protein changes reflected a
decrease in the apoptotic response of the resistant clones,
Western blot analysis on parent and resistant cell extracts
was done to assess the expression levels of some key mol-
ecules related to apoptosis. The marked increased of the
anti-apoptotic protein Bcl2, concomitantly with a
decrease in caspase-3 activation found in the resistant
clones would support the inference from proteomic anal-
ysis that the 4-ABP-resistant clones would have stronger
resistance to apoptosis than their parental counterpart.
Western blot analysis also indicated that the 4-ABP-resist-
ant clones had lower levels of MAD2 than the parental
line. Down-regulation of MAD2, a component of the
mitotic spindle checkpoint pathway, has been linked to
inhibition of anticancer drug-induced apoptosis by up-
regulating Bcl-2 [16]. Thus, our results support this func-
tional link between the status of MAD2 and apoptosis,
confirming that down-regulation of MAD2 expression
would probably help cells evade mitotic arrest and apop-
tosis induced by the DNA-damaging agent 4-ABP.
A further finding in our resistant clones is an overall per-
turbation in cell metabolism and energy pathways. The
expression of enzymes involved in glycolysis (TPI) oxida-
tive phosphorylation (NDUFS3) and ketogenesis
(HIBICH) was reduced, suggesting that all these pathways
were somehow decelerated.
It is of interest that ANXA2, a membrane trafficking pro-
tein, was over-expressed in our resistant cells, since its up-
regulation has already been reported in a doxorubicin-
resistant cancer cell line [17]. So far, the physiological sig-
nificance of enhanced annexin expression in resistance
cells is still unclear.
Interestingly, each of the 4-ABP resistant clones showed its
own expression pattern for some proteins involved in var-
ious biological processes such as cell transformation and
migration (TAGNL2), glycolysis (GAPDH) and regulation
of Ca2+ homeostasis (CALR) [18-20]. These differences are
not altogether surprising, since it cannot be excluded that
cells somehow gained a selective advantage through dif-
ferent strategies that translate as increased carcinogen
resistance. The low abundance of GAPDH and of CALR
Table 1: Proteins identified by LC-MS/MS, showing different expression levels in the different cell lines. Detailed information on 
peptides/proteins identification is reported in Additional File 2.
Spot # Protein identified Symbol Swiss-Prot pI Theor./Exp.b) MW (kD) Theor./Exp.b) #pept. c) Cov% d) Score e)
46 Programmed cell death 6-interacting protein PDCD6IP Q8WUM4 6.13/6 96/95 15 17 93.9
146 Calreticulin CALR P27797 4.3/4.3 48/60 36 62 187.0
206 Aldehyde dehydrogenase 1A3 a ALDH1A3a P47895 6.9/6.4 56/56 20 25 108.6
207 Aldehyde dehydrogenase 1A3 b ALDH1A3b P47895 6.9/7 56/56 19 28 123
349 Elongation factor Tu TUFM P49411 7.3/7.5 49/46 12 30 64.2
431 3-Hydroxyisobutyl Coenzyme A hydrolase HIBCH Q53GA8 8.4/7.4 43/43 16
463 Glyceraldehyde-3-phosphate dehydrogenase GAPDH P04406 8.6/8 36/37 10 27 57.1
479 Annexin A2 ANXA2 P07355 7.6/8.7 38/37 11 33 81.5
680 Transgelin-2 TAGLN2 P37802 8.4/5.8 22/21 3 19 25.1
744 Fatty acid-binding protein FABP4 P15090 6.8/6 14/14 39 73 145.9
801 Lamin-A/C LMNA P02545 6.6/6.2 74/75 35 41 197.6
841 94 kDa glucose-regulated protein GRP94 P14625 4.7/4.7 92/95 15 18 105.2
906 NADH-ubiquinone oxidoreductase 30 kDa subunit NDUFS3 O75489 6.9/5 30/28 10 46 84.3
912 Triosephosphate isomerase TPI P60174 6.5/6 26/27 12 42 77.1
a) Arbitrary label assigned to the different isoforms.
b) Theor.: theoretical, data-based annotations; Exp.: experimental, from 2-D gels.
c) # pept.: number of valid peptide matches found for the given protein
d) Cov%: the percent ratio of all amino acids from valid peptide matches to the total number of amino acids in the protein.
e) Score: the protein score is a function calculated from the individual normalized z-scores of validated peptides. Peptide z-score refers to the 
distribution of calculated scores compared to that of random peptide sequences in order to find the mean and variance http://www.phenyx-
ms.com. Database redundancy is handled and solved by the Phenyx software. If a protein shares all its validated peptides with another one, it is 
considered a subset and will not appear in the best-scoring protein list. It appears in the protein Details panel under Subset for the principal and 
better scoring parameters. Therefore the entries reported (Swiss_Prot AC) refer exclusively to the best-scoring protein found by the search 
engine.Proteome Science 2007, 5:6 http://www.proteomesci.com/content/5/1/6
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only in clone RT5 might be one of the mechanisms used
by these resistant cells to halt their apoptotic response to
death stimuli. Numerous studies have reported a pro-
apoptotic role of GAPDH [19] and its down-regulation
might point to a quenching of the apoptotic pathway,
although it could also simply reflect a modulation in the
rate of glycolysis. Down-regulation of CALR was recently
observed in a melphalan-resistant MCF-7 breast cancer
cell line [20], suggesting that it might be important in the
development of resistance.
Conceivably, different 4-ABP-resistant clones might also
use different molecular factors to lower their apoptotic
response. This possibility might be uphold by the obser-
vation that clone RT11 had a reduced abundance of the
pro-apoptotic PDCD6IP protein, but not clone RT5. This
protein interacts with apoptosis-related protein such as
PDCD6 and endophilin and its down-regulation may be
a link to cell death resistance [21].
Conclusion
In this study we highlighted the importance of the effects
on the expression of proteins related to membrane traf-
ficking and apoptotic pathways in conferring resistance to
the carcinogen 4-ABP. These two processes have also been
evoked for the development of chemoresistance
[4,22,23], suggesting that they might serve as signatures
for cardinal mechanisms by which cells develop resistance
to the action of cytotoxic drugs and probably to carcino-
gens, so they could be potential biomarkers of resistance
and cancer risk.
It is of course not straightforward to correlate alterations
in the expression of every single protein and resistance to
4-ABP. A note of caution is therefore due here. The unique
expression patterns in the resistant clones may be just a
phenotype of these cell populations and may make no
direct contribution to resistance. It is still not clear
whether the resistant clones are the result of a transforma-
tion of the RT112 cell line by 4-ABP or of a selection of
subclones inherently present among RT112 cells.
Materials and methods
Cell cultures
The human papillary non-metastatic bladder cancer cell
line RT112 was kindly provided by Prof. Alberto Bardelli
(Institute for Cancer Research and Treatment, IRCC, Can-
diolo, Torino, Italy). Cells were cultured in RPMI 1640
medium supplemented with 10% (v/v) FBS, 1% penicil-
lin-streptomycin solution (10.000 units penicillin-G and
10 mg streptomycin per mL) and 1% L-glutamine solu-
tions (2 mM). Media components were all from Sigma
(Italy).
Carcinogen treatment and development of resistant cell 
lines
4-ABP was dissolved in DMSO (Sigma) and activated in
NADPH generating system solution (0.27 mM NADP, 5
mM glucose 6-phosphate, 0.45 mM MgCl2, 0.45 mM KCl
and 200 mM Tris-HCl, Sigma) containing 0.4 mg/mL Aro-
clor 1254-induced S9 rat liver extract (BD Italy) for 2 h at
37°C. Cells were treated with the carcinogen for 4 h at
37°C then washed and resuspended in complete
medium. Resistant cells were established by two treat-
ments with 125 ng/mL 4-ABP, the concentration causing
99% death of RT112 cells. Treatment was repeated after
cells surviving the first round had recovered exponential
growth. Single-cell clones were obtained by limiting dilu-
tion. The relative resistance of isolated clones was evalu-
ated by treating 5 × 105  cells with appropriate
concentrations of the carcinogen ranging from 75 to 175
ng 4-ABP/mL. Relative resistance of the treated cultures
was normalized to the plating efficiency of the untreated
controls. The full development and characterization of the
resistant cell lines will be reported in a forthcoming pub-
lication (F. Saletta et al., submitted).
Cell lysis and protein solubilization for 2-DE
Cells at 80% confluent were harvested by scraping,
washed three times with ice-cold 10 mM PBS and pel-
leted. Pellets (5 × 106 cells/pellet) were shock-frozen in
liquid nitrogen and stored at -80°C until further process-
Relative changes in caspase-3, Bcl-2, Bax, Mad2 protein levels  in the human bladder cancer cell line RT112 and in 4-ABP  resistant clones RT5 and RT11, by Western blot analysis Figure 3
Relative changes in caspase-3, Bcl-2, Bax, Mad2 protein levels 
in the human bladder cancer cell line RT112 and in 4-ABP 
resistant clones RT5 and RT11, by Western blot analysis. 
Levels of β-tubulin were used as a normalizing factor for total 
amount of protein loaded.Proteome Science 2007, 5:6 http://www.proteomesci.com/content/5/1/6
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ing. Cell lysis and protein extraction was done in a solu-
tion containing 5 M urea, 2 M thiourea, 2% CHAPS, 2%
Zwittergent and a mixture of protease inhibitors (com-
plete, mini EDTA-free cocktail, Roche). DeStreak reagent
(100 mM) (GE Healthcare, Italy) was added in order to
protect cysteinyl groups and prevent non-specific oxida-
tion. The suspension was incubated for 40 minutes at 4°C
on a mixing wheel. Cell debris was removed by centrifu-
gation at 15,000 × g for 15 min, then the supernatant was
aliquoted and stored at -80°C. Protein concentration was
determined using the PlusOne 2-D Quant kit (GE Health-
care, Italy).
2-DE
For each gel, 300 μg of total protein were dissolved to a
final volume of 250 μL in the re-hydration solution (5 M
urea, 2 M thiourea, 2% CHAPS, 2% Zwittergent, 100 mM
DeStreak and 0.5% IPG buffer pH 3–10 linear, GE Health-
care, Italy), and then applied on immobilized pH 3–10
linear gradient strips (IPG strip, GE Healthcare, Italy). The
strips were hydrated on an IPGphor apparatus (GE
Healthcare, Italy) for 16 h at 30 V/h, then focused for 26
h until 50,000 Vhr. After the first-dimension run, proteins
were reduced by incubating individual strips for 15 min in
a solution containing 50 mM Tris-HCl pH 8.8, 6 M urea,
30% glycerol, 2% SDS, 60 mM dithiothreitol (DTT, GE
Healthcare, Italy). Proteins were then alkylated by incu-
bating the strips for 15 min in a similar solution, with DTT
replaced by 100 mM iodoacetamide. The strips were
embedded in 0.7% (w/v) agarose on the top of 1 mm-
thick acrylamide gels cast at 7.5–17.5%. Proteins were
separated by mass by electrophoresis at 10 mA/gel. This
was done overnight, at 4°C, in a running buffer composed
of 25 mM Tris, 250 mM glycine, 0.1% SDS. Gels were
rinsed three times with de-ionised H2O, fixed for 1 hour
in an aqueous solution with 50% methanol and 7% acetic
acid, and rinsed again with de-ionised H2O. Finally, gels
were stained with colloidal Coomassie Blue (Pierce) for
4–5 hours then extensively washed with de-ionised H2O
[24].
Three replicate gels were run for each experimental condi-
tion (parental cell lines and two resistant clones).
Stained gels were scanned at 16-bit resolution (Expression
1680 Pro, Epson) and the resulting TIFF images were ana-
lysed with Progenesis Workstation software (v2005, Non-
linear Dynamics, UK). The Progenesis automatic analysis
protocol for the images of the nine gels included spot
detection, warping, background subtraction, average gel
creation, matching and reference gel modification. Spot
volumes were normalized against the total volume of all
the spots in the gel. Average gels were generated by the
software for spot pattern comparison. They are a statistical
combination of the gels in a group, showing mean spot
values with the associated error, providing information
about spot variability within the gel set. An average gel
was created for each experimental group by combining
the three replicates. The criterion for including a spot in
the average gel was that any spot must be present in all
replicates. Spot editing (spot splitting corrections and
match editing) was done sparingly, and only on selected
complex areas of the gel.
Statistical analysis
Statistical comparisons of the individual protein abun-
dance in the three cell clones (one-way ANOVA) and
between-groups comparisons (multiple comparison test,
Tukey Kramer HSD, p < 0.05) were computed using JMP
v6 software (SAS Institute Inc.).
Protein identification by mass spectrometry
In-gel digestion was done as previously described [24].
Briefly, the spots of interest were excised manually from
the gel and digested with sequencing-grade modified
trypsin. Aliquots of the supernatant containing tryptic
peptides were directly analysed by mass spectrometry.
Liquid chromatography (reverse-phase microbore-LC)-
tandem mass spectrometry (LC-MS/MS) was done as pre-
viously reported [24] using a Surveyor system (autosam-
pler and MS pump) coupled to an ion-trap mass
spectrometer LCQ Deca XPPlus  (Thermo Finnigan)
equipped with a standard electrospray source, operated in
positive ion mode, with an ion sprayer voltage of 4.6 kV
and capillary temperature of 220°C.
Data were acquired sequentially in MS mode (scan range
of 450–2000 amu), and in data-dependent mode, record-
ing the MS/MS spectra of the three most intense ions of
each MS scan. The MS/MS spectra were acquired with an
isolation width of 3.0 amu and normalized collision
energy of 45%. Raw MS/MS data from each LC run were
transformed into dta files using the instrument software
(BioWorks, rev. 3.1 SR1), with automatic selection of
individual MS/MS spectra.
Tandem mass spectra were analysed using the MS/MS
search engine Phenyx version 1.9 (GenBio, Switzerland)
against the UniProt_Swiss Prot database (version 50.7).
The search was enzymatically constrained for trypsin, and
allowed for one missed cleavage site. Further search
parameters were: no restriction on molecular weight
(MW) and isoelectric point; taxonomy: Homo sapiens;
fixed modification: carbamidomethylation of cysteine;
variable modification: oxidation of methionine.
A summary table is available (see Additional file 2) that
concisely restates the main submission parameters includ-Proteome Science 2007, 5:6 http://www.proteomesci.com/content/5/1/6
Page 8 of 9
(page number not for citation purposes)
ing algorithm, scoring models, thresholds. All informa-
tion concerning peptide identification is available in
Additional file 3, derived from the Phenyx Database/AC/
Peptide view results page.
Western blotting
The electrophoretic pattern of proteins related to apopto-
sis (Bax, Bcl-2, caspase-3) and mitotic checkpoints
(mitotic arrest deficient 2, MAD2) was investigated by
Western blot analysis. Cells extracts were prepared by lys-
ing cells in the lysis buffer (Triton X-100, 1 M Tris, 5 M
NaCl) in the presence of aprotinin, leupeptine and PMSF
as protease inhibitors, for 30 minutes on ice. Insoluble
materials was pelletted at 13,000 × g for 10 minutes at
4°C and the protein concentration was determined using
a Biorad assay kit (BioRad, Milan, Italy).
Total cellular proteins (30 μg protein/lane) were sepa-
rated on SDS-10% polyacrylamide resolving gels using the
Mini Protean II electrophoresis system at 100 V, for 2
hours (Bio-Rad, Milan, Italy). Proteins were transferred to
nitrocellulose transfer membrane (Whatman, UK) using
the transfer buffer (50 mM Tris, 100 mM glycine, SDS
0.01%, 20% methanol) and the Bio-Rad Trans-blot sys-
tem (55 V, 2 h).
Blots were rinsed with TBS-T buffer (10 mM Tris-HCl pH
8, 150 mM HCl, 0.05% v/v Tween-20) and blocked in
TBS-T, 5% w/v non-fat dried milk (Nestlé, Italy) for 2 h.
After overnight incubation with primary antibody diluted
1:300 in TBS-T, 5% non-fat dried milk, (rabbit polyclonal
antibodies: β-tubulin H-235, caspase-3 H-277, MAD2 FL-
205, Bcl-2 N-19, Bax N-20; mouse monoclonal antibody
caspase-3 E-8; Santa Cruz Biotechnology, USA) blots were
washed with TBS-T and incubated with secondary anti-
body at 1:1000 for 2 h. Peroxidase-conjugated anti-mouse
or anti-rabbit IgG HRP (Santa Cruz, Biotechnology, USA)
were used as secondary antibodies.
Blots were revealed using enhanced chemiluminescence
(ECL) (GE, Milan, Italy) and scanned as 16-bit images
(Expression 1680 Pro, Epson). The resulting TIFF images
were analysed using the Progenesis software (v2005, Non-
linear Dynamics, U.K, Nonlinear Dynamics, UK). Expres-
sion data were normalized relative to β-tubulin.
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